The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Illumina, Federal Circuit, DNA, pregnancy, biotechnology, Roche, Ariosa, foetal, patents, court, ruling, en banc